权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Leadership Center Administration

领导中心管理

基本信息

批准号：
10363632
负责人：
ROBERT A WOOD
金额：
$ 272.01万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-03-01 至 2024-02-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10363632
关键词：
Administrator Adolescence Adult Affect Allergy to eggs Biological Assay Biological Markers Child Clinical Clinical Protocols Clinical Research Clinical Trials Collaborations Complex Conflict (Psychology)Cost efficiency Data Analyses Data Collection Development Disease Emergency Situation Ensure Equilibrium Food Hypersensitivity Foundations Funding Funding Opportunities Goals Grant Immune response Immunologist Immunotherapy Impairment Individual Infrastructure International Investigation Laboratories Lead Leadership Life Malnutrition Milk Hypersensitivity Monitor Morbidity - disease rate National Institute of Allergy and Infectious Disease Nut Hypersensitivity Occupational activity of managing finances Oral Performance Pharmaceutical Preparations Phase Population Positioning Attribute Prevalence Prevention Prevention approach Prevention strategy Productivity Protocols documentation Publications Publishing Quality of life Reaction Research Research Personnel Resources Science Site Standardization Structure Therapeutic Time Training Vision Wheat Hypersensitivity Wood material Work Workload base biobank biomarker discovery clinical trial implementation cost efficient effective therapy experience food allergen innovation next generation novel operation patient subsets protocol development sound surveillance study

项目摘要

Summary Food allergy research has increased dramatically over the past 15 years providing us with potential therapeutic and prevention strategies. The overarching goal of the research agenda proposed in this application is to position CoFAR as the international leader in the study of food allergy, including optimal characterization of the disease and development of the next generation of treatments. The research agenda will be based first and foremost on the best possible science, but to maximize productivity we will also need to plan judiciously so that all available resources can be used to their utmost capacity. Therefore, the research agenda will need to carefully select and stage protocols based not just on their potential to advance the field, but also with careful consideration regarding other novel treatments that may be under development, and how one study may inform the next. Finally, the overall research strategy will also need to balance the work load of the SACCC and each CRU in the consortium. This overall agenda will be accomplished through the following major components: 1) To implement a leadership team capable of providing optimal administration of the Consortium, including financial, operational, and managerial aspects, as well as protocol development and implementation, data collection and analysis, and publications and presentations, with judicious financial management. Dr. Robert Wood will lead this team, with co-PIs Drs. Wesley Burks and Marsha Wills-Karp, who will lead the Biomarker Facility and Opportunity Fund, respectively. The team will also include a financial administrator as well as a highly experienced grants management group at Johns Hopkins. The leadership team will work closely with the NIAID and SACCC, together providing day-to-day management of all clinical operations within the consortium. 2) To develop the necessary committee structure to guide and implement the Consortium’s administrative and clinical operations. 3) To develop a structure of financial management that will make optimal use of all CoFAR funds and resources. 4) To integrate the Biomarker Facility into each clinical protocol. 4) To maximally leverage the resources and potential of the Opportunity Fund to expand the mechanistic study of food allergy and its treatment. It is anticipated that a minimum of 3 protocols, including both clinical trials and non-interventional studies, will be initiated and completed over the seven-year funding period, and this could rise to 5 or even 6 protocols depending on the size, duration, and complexity of each study. If successful, this research agenda will define not just the next 7 years of CoFAR, but will also establish the platform for the next decade(s) of food allergy research.

总结